BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.- Ukraine to get up to 100 French-made Rafale fighter jets
- Figure out How to Assess the Unwavering quality of SUVs for Seniors
- Flu cases are rising with a strain that makes older people sicker
- IDF finds weapon of slain hostage Capt. Daniel Perez in booby-trapped Gaza compound
- 'Euphoria' releases Season 3 photos with Zendaya, Sydney Sweeney, Jacob Elordi and others: See them
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure
- Why home maintenance deserves a spot in the annual health and budget plans
